Houston Methodist part of national consortium to develop vaccine against herpesviruses

Houston Methodist researchers will be part of a national consortium funded by an up to $49 million award from the U.S. Government’s Advanced Research Projects Agency for Health (ARPA-H) to develop a vaccine against two of the most common and destructive strains of herpesviruses that latently infect a majority of Americans and can lead to acute infections, multiple forms of cancer, autoimmune disease and birth defects.